933781-52-3

Basic information

• Product Name: trans-4-(trifluoromethyl)cyclohexanecarboxamide
• Synonyms: trans-4-(trifluoromethyl)cyclohexanecarboxamide
• CAS NO: 933781-52-3
• Molecular Weight: 195.185
• Mol File: 933781-52-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 270.3±35.0 °C(Predicted)
• Density: 1.235±0.06 g/cm3(Predicted)
• CAS DataBase Reference: trans-4-(trifluoromethyl)cyclohexanecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: trans-4-(trifluoromethyl)cyclohexanecarboxamide(933781-52-3)
• EPA Substance Registry System: trans-4-(trifluoromethyl)cyclohexanecarboxamide(933781-52-3)

Safety Data

• Hazardous Substances Data: 933781-52-3(Hazardous Substances Data)

Upstream product

• 934330-05-9 trans-4-(trifluoromethyl)cyclohexanecarbonyl chloride 
• 133261-33-3 trans-4-trifluoro-methyl-cyclohexanecarboxylic acid 

Downstream Products

• 1360622-20-3 N-(trans-4-trifluoromethyl-cyclohex-1-yl)-2-{2,6-dichloro-3-[(2,2-dimethyl-propionylamino)-methyl]-phenylamino}-6-(2,2,2-trifluoroethoxy)-7-fluoro-1H-benzimidazole-5-carboxylic acid amide 
• 1218943-32-8 trans-4-trifluoromethylcyclohexanamine hydrochloride 
• 1242270-09-2 N-(trans-4-trifluoromethyl-cyclohex-1-yl)-2-fluoro-4-methylamino-5-nitro-benzoic acid amide 
• 1242270-11-6 N-(trans-4-trifluoromethyl-cyclohex-1-yl)-2-(2,2-difluoro-ethoxy)-4-methylamino-5-nitro-benzoic acid amide 
• 1242269-83-5 N-(trans-4-trifluoromethyl-cyclohex-1-yl)-2-(2,2-difluoro-ethoxy)-4-methylamino-5-amino-benzoic acid amide 
• 1360622-01-0 N-(trans-4-trifluoromethyl-cyclohex-1-yl)-2-{2,6-dichloro-3-[(2,2-dimethyl-propionylamino)-methyl]-phenylamino}-6-(2,2-difluoro-ethoxy)-1-methyl-1H-benzimidazole-5-carboxylic acid amide 

Relevant articles and documents

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

NEW COMPOUNDS

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R1, R2, R6, R7, R8 have meanings given in the description.